Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers

Clinical Pharmacokinetics

Volumn 32, Issue SUPPL. 1, 1997, Pages 43-49

  Gardner, Mark J ^a,c   Baris, Barbara A ^a   Wilner, Keith D ^a   Preskorn, Sheldon H ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Via Christi Rehabilitation Center   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; LIVER ENZYME; NORDAZEPAM; SERTRALINE;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEADY STATE;

EID: 0031019242     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199700321-00007     Document Type: Review

References (21)

1. Bertilsson L, Henthorn TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquine, hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348-55
2. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195-212
3. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the effects of E3810 and omeprazole on diazepam pharmacokinetics in extensive and poor metabolisers of S-mephenytoin [abstract]. Clin Pharmacol Ther 1994; 55: 141
4. Wilkinson G, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989; 43: 53-76
5. Yasumori T, Nagata K, Yang SK, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate contentration-dependent manner. Pharmacogenetics 1993; 3 (6): 291-301
6. Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131-7
7. Weinfeld RE, Postmanter HN, Khoo KC, et al. Rapid determination of diazepam and nordiazepam in plasma by electron capture gas-liquid chromatography. Application in clinical pharmacokinetic studies. J Chromatogr 1977; 143: 581-95
8. Tremaine LM, Joerg EA. Automated gas chromatographic - electron-capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 496: 423-9
9. Greenblatt DJ, Divoll MK, Soong MH, et al. Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate and intravenous diazepam. J Clin Pharmacol 1988; 28: 853-9
10. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997; 32 Suppl. 1: 31-6
11. Apseloff G, Wilner KD, Gerber N, et al. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997; 32 Suppl. 1: 37-42
12. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52: 479-486
13. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50: 10-15
14. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256-61
15. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions. II. J Clin Psychopharmacol 1990; 10: 213-7
16. Lemberger L, Rowe H, Bosomworth JC, et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988; 43: 412-9
17. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203-20
18. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993; 54 Suppl. 9: 14-34
19. Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994; 56: 471-6
20. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5
21. Sellers EM. Presentation to the FDA Psycho pharmacology Advisory Committee meeting; Washington DC: April, 1993